+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
E

Actively Recruiting

Researchers are evaluating a new blood test called Avantect to see if it can detect pancreatic cancer early in people aged 50 to 84 who have recently been diagnosed with type 2 diabetes or have elevated blood sugar levels. Pancreatic cancer is very deadly because it is often found too late for surgery, so early detection could improve treatment options. This trial aims to find out if Avantect can identify pancreatic cancer signals before symptoms appear. Participants will have their blood tested using the Avantect device at three scheduled visits over one year. If the test detects pancreatic cancer markers, participants and their doctors will be informed to arrange further imaging scans like MRI or CT to confirm the diagnosis. The study will track participants remotely for three years after consent to monitor any pancreatic cancer diagnosis or mortality through health registries. During the study, participants will provide blood samples and complete anxiety questionnaires at each visit. Researchers will assess the tests accuracy by measuring its sensitivity and specificity after three years. They will also evaluate how well the test predicts cancer presence, the stage of detected cancers, and surgery rates. The study offers free diagnostic testing and includes ongoing safety and health monitoring for all participants.

Age: 50Years - 84YearsAll GendersPhase Not Applicable
31 locations